Elafibranor - Ipsen
Alternative Names: GFT-505; IPN-60190; IQIRVO; IqirvoLatest Information Update: 18 May 2025
At a glance
- Originator Genfit
- Developer Genfit; Ipsen
- Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Antihyperlipidaemics; Hepatoprotectants; Organic sulfur compounds; Phenyl ethers; Propionic acids; Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Primary biliary cirrhosis
- Phase III Primary sclerosing cholangitis
- Discontinued Hepatic fibrosis; Lipid metabolism disorders; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
Most Recent Events
- 07 May 2025 Updated efficacy and pharmacodynamics data from a phase III ELATIVE trial in Primary biliary cirrhosis released by Ipsen
- 28 Apr 2025 Registered for Primary biliary cirrhosis (Combination therapy, Treatment-experienced) in Canada (PO)
- 28 Apr 2025 Registered for Primary biliary cirrhosis (Monotherapy) in Canada (PO)